

## Partnership with Carepath for passive in-home monitoring of COPD patients

- Carepath is a Berlin-based company developing a telehealth platform that passively monitors patients in residential environments
- Carepath's hardware-software platform, NELA, is designed to monitor and measure specific symptoms of a patient including cough
- Carepath will integrate ResAppDx to perform a pilot in Germany on the remote monitoring and management of COPD patients
- ResApp to collect longitudinal data in COPD and secure important experience in the use of passive audio monitoring of patients in-home

**Brisbane, Australia, 16 November 2021** – ResApp Health Limited (ASX:RAP), a leading digital health company developing smartphone applications for the diagnosis and management of respiratory disease, has signed a Joint Development and Pilot agreement with Berlin-based company Carepath Technologies GmbH ("Carepath"). Under the agreement, Carepath will integrate ResApp's smartphone-based respiratory diagnostic test ResAppDx in their NELA platform and perform a pilot in Germany on the remote monitoring and management of COPD patients.

Carepath's NELA is a combination hardware-software solution that places an advanced symptom monitoring device into the home. NELA's custom hardware is equipped with passive sensors, including a far-field microphone array, which are able to monitor symptom progression as a patient moves around their home. Through Carepath's Praxis Portal, patient data is summarised visually, revealing patterns and trends within a patient's symptom progression to support clinical decisions and patient management.

ResAppDx is ResApp's acute respiratory diagnostic test that uses machine-learning technology to analyse signatures in cough sounds to diagnose respiratory disease using a smartphone's inbuilt microphone. It is CE Marked in Europe and TGA approved for ARTG (Australian Register of Therapeutic Goods) listing in Australia. ResAppDx will be used to identify COPD exacerbations in patients monitored with the NELA device. In addition, the pilot will collect longitudinal COPD data from patients which will potentially allow ResApp to incorporate additional functionality into ResAppDx for the monitoring and management of these COPD patients.

**Daniel Young, Carepath's Co-Founder** said: *"Carepath's commitment to developing an exceptional platform for remote patient monitoring is resolute. We see a future where patients receive the highest levels of care, while living at home. There is a high unmet medical need for more effective management and treatment of COPD and globally this market is predicted to grow to US\$4.8 billion by 2026. By*



*embedding ResAppDx into NELA, we add advanced diagnostics for COPD. This combination has the potential to greatly improve the standard of care for COPD patients.”*

**CEO and Managing Director of ResApp, Dr Tony Keating said:** *“Carepath have developed a hardware solution that offers a unique opportunity to manage COPD patients in their own home. We’re excited to be working with the Carepath team on a pilot of ResAppDx in this setting.*

*“Germany has a progressive digital health reimbursement environment (DiGA<sup>1</sup>) to encourage innovative, remote patient management and patient empowerment. It is the ideal market to foster this innovation. This partnership will create value for ResApp, Carepath and our collective shareholders and stakeholders.”*

### **Agreement details**

Carepath and ResApp Health have entered into a Joint Development and Pilot Agreement (“Agreement”) where ResApp licenses the ResAppDx smartphone application to Carepath for use in a pilot on its NELA platform in Germany. The Agreement is for an initial term of two years, after which ResApp and Carepath expect to enter negotiations on the cost of non-exclusive licensing of ResAppDx for the remote monitoring and management of COPD patients in Germany. The agreement is non-exclusive, however ResApp agrees it will not license ResAppDx in Germany on a similar hardware platform for the term of the agreement. Each party will bear its own costs during the pilot.

###

### **About ResApp Health Limited**

ResApp Health Limited (ASX: RAP) is a leading digital health company developing smartphone applications for the diagnosis and management of the respiratory disease. ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware. ResApp’s regulatory-approved and clinically validated products include ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department and primary care settings; and SleepCheck, an at-home sleep apnoea screening app for consumers to self-assess their risk of sleep apnoea. Both products are CE Marked in Europe and TGA approved in Australia. For more information, please visit [www.resapphealth.com.au](http://www.resapphealth.com.au).

### **About Carepath Technologies GmbH**

Carepath Technologies GmbH is a Berlin-based venture developing NELA, an advanced remote patient monitoring platform. NELA combines EDGE computing with AI to passively monitor

---

<sup>1</sup> The German Digital Healthcare Act (Digitale-Versorgung-Gesetz, DVG) introduced “app on prescription” for patients. Approximately 73 million persons covered by the German statutory health insurance are entitled to use a digital health application (Digitale Gesundheitsanwendungen, DiGA) prescribed by a physician and are reimbursed by the health insurance.



patients with chronic pulmonary diseases. The company was founded in 2019 by Mr Adam Dessoky and Mr Daniel Young.

**Contacts**

Dr Tony Keating  
CEO and Managing Director  
+61 430 180 659  
[tony@resapphealth.com.au](mailto:tony@resapphealth.com.au)

Mr Brian Leedman  
Executive Director, Corporate Affairs  
+61 412 281 780  
[brian@resapphealth.com.au](mailto:brian@resapphealth.com.au)

*This ASX announcement was approved and authorised for release by the board of directors of ResApp Health.*